Rhinovirus chemotherapy
Publication type: Journal Article
Publication date: 2006-09-01
scimago Q1
wos Q1
SJR: 1.195
CiteScore: 7.3
Impact factor: 4.0
ISSN: 01663542, 18729096
PubMed ID:
16675037
Pharmacology
Virology
Abstract
Human rhinoviruses (HRV), members of the Picornaviridae family, are comprised of over 100 different virus serotypes. HRV represent the single most important etiological agents of the common cold [Arruda, E., Pitkaranta, A., Witek Jr., T.J., Doyle, C.A., Hayden, F.G., 1997. Frequency and natural history of rhinovirus infections in adults during autumn. J. Clin. Microbiol. 35, 2864-2868; Couch, R.B., 1990. Rhinoviruses. In: Fields, B.N., Knipe, D.M. (Eds.), Virology. Raven Press, New York, pp. 607-629; Turner, R.B., 2001. The treatment of rhinovirus infections: progress and potential. Antivir. Res. 49 (1), 1-14]. Although HRV-induced upper respiratory illness is often mild and self-limiting, the socioeconomic impact caused by missed school or work is enormous and the degree of inappropriate antibiotic use is significant. It has been estimated that upper respiratory disease accounts for at least 25 million absences from work and 23 million absences of school annually in the United States [Anzueto, A., Niederman, M.S., 2003. Diagnosis and treatment of rhinovirus respiratory infections. Chest 123 (5), 1664-1672; Rotbart, H.A., 2002. Treatment of picornavirus infections. Antivir. Res. 53, 83-98]. Increasing evidences also describe the link between HRV infection and more serious medical complications. HRV-induced colds are the important predisposing factors to acute otitis media, sinusitis, and are the major factors in the induction of exacerbations of asthma in adults and children. HRV infections are also associated with lower respiratory tract syndromes in individuals with cystic fibrosis, bronchitis, and other underlying respiratory disorders [Anzueto, A., Niederman, M.S., 2003. Diagnosis and treatment of rhinovirus respiratory infections. Chest 123 (5), 1664-1672; Gern, J.E., Busse, W.W., 1999. Association of rhinovirus infections with asthma. Clin. Microbiol. Rev. 12 (1), 9-18; Pitkaranta, A., Arruda, E., Malmberg, H., Hayden, F.G., 1997. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J. Clin. Microbiol. 35, 1791-1793; Pitkaranta, A., Virolainen, A., Jero, J., Arruda, E., Hayden, F.G., 1998. Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 102, 291-295; Rotbart, H.A., 2002. Treatment of picornavirus infections. Antivir. Res. 53, 83-98]. To date, no effective antiviral therapies have been approved for either the prevention or treatment of diseases caused by HRV infection. Thus, there still exists a significant unmet medical need to find agents that can shorten the duration of HRV-induced illness, lessen the severity of symptoms, minimize secondary bacterial infections and exacerbations of underlying disease and reduce virus transmission. Although effective over-the-counter products have been described that alleviate symptoms associated with the common cold [Anzueto, A., Niederman, M.S., 2003. Diagnosis and treatment of rhinovirus respiratory infections. Chest 123 (5), 1664-1672; Gwaltney, J.M., 2002a. Viral respiratory infection therapy: historical perspectives and current trials. Am. J. Med. 22 (112 Suppl. 6A), 33S-41S; Turner, R.B., 2001. The treatment of rhinovirus infections: progress and potential. Antivir. Res. 49 (1), 1-14; Sperber, S.J., Hayden, F.G., 1988. Chemotherapy of rhinovirus colds. Antimicrob. Agents Chemother. 32, 409-419], this review will primarily focus on the discovery and development of those agents that directly or indirectly impact virus replication specifically highlighting new advances and/or specific challenges with their development.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Antiviral Research
10 publications, 10.1%
|
|
|
Bioorganic and Medicinal Chemistry Letters
6 publications, 6.06%
|
|
|
Journal of Medicinal Chemistry
4 publications, 4.04%
|
|
|
Viruses
3 publications, 3.03%
|
|
|
Medicinal Research Reviews
3 publications, 3.03%
|
|
|
ACS Medicinal Chemistry Letters
3 publications, 3.03%
|
|
|
Future Medicinal Chemistry
2 publications, 2.02%
|
|
|
Virology Journal
2 publications, 2.02%
|
|
|
Pulmonary Pharmacology and Therapeutics
2 publications, 2.02%
|
|
|
Journal of Clinical Virology
2 publications, 2.02%
|
|
|
Bioorganic and Medicinal Chemistry
2 publications, 2.02%
|
|
|
Sub-Cellular Biochemistry
2 publications, 2.02%
|
|
|
Journal of Virology
2 publications, 2.02%
|
|
|
Clinical Microbiology Reviews
2 publications, 2.02%
|
|
|
Emerging Infectious Diseases
1 publication, 1.01%
|
|
|
F1000Research
1 publication, 1.01%
|
|
|
Future Virology
1 publication, 1.01%
|
|
|
Journal of General Virology
1 publication, 1.01%
|
|
|
Current Opinion in Pediatrics
1 publication, 1.01%
|
|
|
Antiviral Therapy
1 publication, 1.01%
|
|
|
Biology
1 publication, 1.01%
|
|
|
Respiratory Research
1 publication, 1.01%
|
|
|
Current Allergy and Asthma Reports
1 publication, 1.01%
|
|
|
Journal of Biomedical Science
1 publication, 1.01%
|
|
|
Tijdschrift voor kindergeneeskunde
1 publication, 1.01%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 1.01%
|
|
|
Chinese Chemical Letters
1 publication, 1.01%
|
|
|
Biochemical Pharmacology
1 publication, 1.01%
|
|
|
Current Opinion in Virology
1 publication, 1.01%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
32 publications, 32.32%
|
|
|
Springer Nature
11 publications, 11.11%
|
|
|
Wiley
9 publications, 9.09%
|
|
|
American Chemical Society (ACS)
8 publications, 8.08%
|
|
|
American Society for Microbiology
6 publications, 6.06%
|
|
|
Taylor & Francis
5 publications, 5.05%
|
|
|
MDPI
4 publications, 4.04%
|
|
|
Georg Thieme Verlag KG
2 publications, 2.02%
|
|
|
Centers for Disease Control and Prevention (CDC)
1 publication, 1.01%
|
|
|
F1000 Research
1 publication, 1.01%
|
|
|
Microbiology Society
1 publication, 1.01%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.01%
|
|
|
SAGE
1 publication, 1.01%
|
|
|
Oxford University Press
1 publication, 1.01%
|
|
|
Hindawi Limited
1 publication, 1.01%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 1.01%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 1.01%
|
|
|
BMJ
1 publication, 1.01%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 1.01%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
99
Total citations:
99
Citations from 2024:
5
(5.05%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.antiviral.2006.03.011
UR - https://doi.org/10.1016/j.antiviral.2006.03.011
TI - Rhinovirus chemotherapy
T2 - Antiviral Research
AU - Patick, Amy K.
PY - 2006
DA - 2006/09/01
PB - Elsevier
SP - 391-396
IS - 2-3
VL - 71
PMID - 16675037
SN - 0166-3542
SN - 1872-9096
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2006_Patick,
author = {Amy K. Patick},
title = {Rhinovirus chemotherapy},
journal = {Antiviral Research},
year = {2006},
volume = {71},
publisher = {Elsevier},
month = {sep},
url = {https://doi.org/10.1016/j.antiviral.2006.03.011},
number = {2-3},
pages = {391--396},
doi = {10.1016/j.antiviral.2006.03.011}
}
Cite this
MLA
Copy
Patick, Amy K.. “Rhinovirus chemotherapy.” Antiviral Research, vol. 71, no. 2-3, Sep. 2006, pp. 391-396. https://doi.org/10.1016/j.antiviral.2006.03.011.